Panacell Biotech Co., Ltd. (CEO Seung-ho Choi), a company specializing in research and development of biomaterials and cell therapy, and Panacell Co., Ltd. (CEO Mi-joo Kim), a stem cell-based beauty company, announced on the 27th that they signed a memorandum of understanding (MOU) at the Panacell Biotech headquarters in Jung-gu, Incheon, outlining cooperation on exosome-utilizing products and related businesses.
This agreement was established to combine the technological prowess and business capabilities of both companies to promote joint research and development of exosome-related products and to expand the related market.
The main contents of the agreement include cooperation in product planning and research and development using exosome raw materials, technical and business consultations for technological advancement and quality improvement, and joint establishment of brand and business strategies for entry into domestic and international markets.
Panacelbiotech is a biotechnology-focused company that has officially registered its human umbilical cord Wharton jelly-derived mesenchymal stem cell culture extract, developed by its own research team, with the International Organization for Standardization (INCI). Furthermore, it obtained approval for a cell processing facility from the Ministry of Food and Drug Safety in 2021, and its partner medical institution, Midas Hospital, was designated as an advanced regenerative medicine provider in 2024, establishing a technological foundation in the fields of cellular immunotherapy and stem cell application technology.
Choi Seung-ho, CEO of Panacell Biotech, said, “We have confirmed the possibility of developing functional cosmetic raw materials based on stem cell culture technology,” and “We plan to pursue the development of high-functionality exosome products through collaboration with Panacell based on research ethics and safety.”
Panacela established a new corporation through this agreement, leveraging the management expertise of Haeum International, which operates the golf and outdoor beauty brand Duonme. The company aims to combine its biotechnology expertise with its brand planning capabilities to launch a next-generation stem cell-based beauty brand.
Kim Mi-joo, CEO of Panacela, said, “We plan to introduce differentiated exosome beauty products based on Panacela Biotech’s stem cell technology,” and “We will build a premium beauty lineup targeting both domestic and international markets.”
You must be logged in to post a comment.